Get the Stockscreener App
0.7016
1.32%
-0.0094
After Hours:
.70
-0.0016
-0.23%
Aprea Therapeutics Inc stock is traded at $0.7016, with a volume of 149.97K.
It is down -1.32% in the last 24 hours and down -22.06% over the past month.
Aprea Therapeutics Inc is a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers. It develops small molecule inhibitors designed to exploit genetic mutations in cancer to widen the therapeutic window and is intended to make treatments more effective at destroying cancer cells while sparing healthy tissue. The company's pipeline of clinical and preclinical programs includes APR-1051, a WEE1 inhibitor; ATRN-119 (Mosipasertib), an oral small molecule inhibitor of ataxia telangiectasia and Rad3-related, or ATR; and an early-stage program, APR-1602. These candidates are being developed for broad applications in cancer treatment.
See More
Previous Close:
$0.711
Open:
$0.72
24h Volume:
149.97K
Relative Volume:
0.07
Market Cap:
$8.04M
Revenue:
$285.80K
Net Income/Loss:
$-12.60M
P/E Ratio:
-0.3554
EPS:
-1.9743
Net Cash Flow:
$-13.44M
1W Performance:
-0.31%
1M Performance:
-22.06%
6M Performance:
-51.01%
1Y Performance:
-57.18%
1-Day Range:
$0.7001
$0.7391
1-Week Range:
$0.651
$0.7409
52-Week Range:
$0.548
$2.11
Aprea Therapeutics Inc Stock (APRE) Company Profile
Name
Aprea Therapeutics Inc
Sector
Industry
Phone
215-948-4119
Address
3805 OLD EASTON ROAD, DOYLESTOWN, MA
Compare APRE vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
APRE
Aprea Therapeutics Inc
|
0.7016 | 8.14M | 285.80K | -12.60M | -13.44M | -1.9743 |
VRTX
Vertex Pharmaceuticals Inc
|
443.92 | 109.85B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
775.53 | 80.38B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
785.07 | 47.60B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
327.25 | 42.63B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
312.19 | 33.72B | 5.36B | 287.73M | 924.18M | 2.5229 |
Aprea Therapeutics Inc Stock (APRE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-28-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Dec-16-20 | Initiated | Berenberg | Buy |
| Sep-29-20 | Resumed | JP Morgan | Neutral |
| Jun-22-20 | Initiated | H.C. Wainwright | Neutral |
| Apr-21-20 | Initiated | Robert W. Baird | Outperform |
| Oct-28-19 | Initiated | JP Morgan | Neutral |
| Oct-28-19 | Initiated | Morgan Stanley | Equal-Weight |
| Oct-28-19 | Initiated | RBC Capital Mkts | Outperform |
View All
Aprea Therapeutics Inc Stock (APRE) Latest News
Aprea reports partial response in APR-1051 cancer trial - MSN
Aprea Therapeutics, Inc.Common Stock (NQ: APRE - FinancialContent
Aprea Reports Partial Response in APR-1051 Cancer Trial - MyChesCo
Former Aprea CEO Christian Schade joins Frazier after Halda sale - Stock Titan
APRE PE Ratio & Valuation, Is APRE Overvalued - Intellectia AI
Stocks in play: CGI Inc. - Barchart.com
APRE SEC FilingsAprea Therapeutics, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Soleus entities and Guy Levy report 1.27M shares in Aprea (NASDAQ: APRE) - Stock Titan
Aprea Therapeutics (APRE) CFO buys pre-funded and common warrants - Stock Titan
Aprea Therapeutics (APRE) director buys pre-funded and common stock warrants - Stock Titan
Aprea Therapeutics Announces Closing of Oversubscribed $30 Million Private Placement - bitget.com
Aprea Therapeutics Raises $30M to Advance Oncology Pipeline - TipRanks
Weekly Earnings: Is Aprea Therapeutics Inc stock a buy or sell2026 Big Picture & Fast Gain Stock Tips - baoquankhu1.vn
Aprea Therapeutics closes $30 million private placement - Investing.com
Aprea Therapeutics closes $30 million private placement By Investing.com - Investing.com India
Aprea closes oversubscribed $30M private placement to fund APR-1051 clinical expansion - TradingView
Aprea Therapeutics (NASDAQ: APRE) closes $30M oversubscribed funding - Stock Titan
Aug Fed Impact: How does Aprea Therapeutics Inc perform in inflationary periods2026 Volume Leaders & AI Optimized Trade Strategies - baoquankhu1.vn
Aprea Therapeutics (NASDAQ:APRE) Given Outperform Rating at Wedbush - Defense World
Aprea reports 2025 results, early data for APR-1051 trial - MSN
Aprea Therapeutics Announces $30 Million Private Placement - The Globe and Mail
APRE: Wedbush Reiterates 'Outperform' Rating with $7 Target | AP - GuruFocus
Aprea reports confirmed tumor response in WEE1 inhibitor trial - Investing.com
Aprea reports confirmed tumor response in WEE1 inhibitor trial By Investing.com - Investing.com South Africa
Aprea Therapeutics raises $30 million in private placement By Investing.com - Investing.com Australia
Aprea Therapeutics (NASDAQ:APRE) versus Ocugen (NASDAQ:OCGN) Head-To-Head Comparison - Defense World
Aprea’s $30 million funding may lead to significant dilution with the 2028 deadline approaching - bitget.com
Aprea Therapeutics, Inc. announced that it has received $30.0204 million in funding from Soleus Capital LLC, Vestal Point Capital, LP, Squadron Capital Management Llc - MarketScreener
Aprea Therapeutics (Nasdaq: APRE) secures $30M and reports WEE1 trial response - Stock Titan
Aprea Therapeutics, Inc. announced that it expects to receive $30.0204 million in funding from Soleus Capital LLC, Vestal Point Capital, LP, Squadron Capital Management Llc and other investors - marketscreener.com
Aprea Therapeutics Highlights Positive Emerging Clinical Activity for WEE1 Inhibitor, APR-1051, with a Confirmed Partial Response in the Ongoing Phase 1 ACESOT-1051 Trial - bitget.com
Aprea Reports Confirmed Partial Response In APR-1051 Trial And Announced $30M Private Placement - RTTNews
Aprea Therapeutics raises $30 million in private placement - Investing.com
12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga
Cancer drug developer raises $30M to fund lead trial into 2028 - Stock Titan
After a 50% drop, an endometrial tumor shrank again on APR-1051 - Stock Titan
EPS Watch: How cyclical is Aprea Therapeutics Incs revenue streamQuarterly Trade Report & Free Safe Capital Growth Stock Tips - baoquankhu1.vn
Risk Hedge: How cyclical is Aprea Therapeutics Incs revenue stream - baoquankhu1.vn
Aprea Therapeutics, Inc. (NASDAQ:APRE) Short Interest Update - Defense World
Aprea Advances Dual DDR Programs as Early Signals of Drug Activity Strengthen - MSN
Aprea to present at Oppenheimer Healthcare Conference - MSN
Unpacking Q4 Earnings: Halozyme Therapeutics (NASDAQ:HALO) In The Context Of Other Therapeutics Stocks - Barchart.com
Price Action: Is Aprea Therapeutics Inc affected by consumer sentimentMarket Movers & Daily Chart Pattern Signals - baoquankhu1.vn
Market Review: Is Aprea Therapeutics Inc a potential multi baggerRisk Management & Consistent Growth Stock Picks - baoquankhu1.vn
Aprea Reports 2025 Results, Early Data for APR-1051 Trial - MyChesCo
Aprea Therapeutics advanced cancer trial shows promising results, stock soars - MSN
[EFFECT] Aprea Therapeutics, Inc. SEC Filing - Stock Titan
Aprea Therapeutics Inc Stock (APRE) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.51%
1.75%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):